# OncoMed Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oncomed-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.oncomed.com
- Total disclosed funding: $104M
- Latest round: Series B (Dec 12, 2008)
- Investors on record: 12

## About

OncoMed Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The company utilizes cutting-edge research to advance its portfolio of monoclonal antibodies and cancer stem cell therapies.OncoMed Pharmaceuticals, Inc. was founded in 2004 in Redwood City, US, focusing on drug development for oncology. The company underwent a significant funding event in July 2013, raising USD 82 million in its IPO by selling 4.8 million shares at USD 17 per share. OncoMed has completed a total of 10 deals to date.OncoMed Pharmaceuticals specializes in creating monoclonal antibodies aimed at targeting cancer stem cells. Their product offerings include investigational therapies designed to disrupt cancer cell proliferation and survival, which are intended to improve treatment outcomes for patients with various types of cancer.In 2018, OncoMed Pharmaceuticals reported a revenue of USD 44.42 mn, with an EBITDA of USD -8.35 mn, indicating a loss during that year.OncoMed Pharmaceuticals plans to utilize its most recent funding from July 2013 to enhance research and development efforts for new oncology products. The company aims to expand its market presence in North America and Europe, targeting specific cancer indications by 2025. Ongoing collaborations are expected to facilitate the commercialization of promising therapies as they progress through clinical trials.

## Funding rounds

- Series B, Dec 12, 2008, $47M — Adams Street Partners, Bay Partners, Delphi Ventures, Latterell Venture Partners, US Venture Partners, De Novo Ventures, Vertical Group, Nomura Asset Management, GSK Ventures
- Series C, Jul 16, 2008, $43M — Adams Street Partners, Bay Partners, Latterell Venture Partners, Morgenthaler Ventures, US Venture Partners, De Novo Ventures, Vertical Group, Phase4 Partners, GlaxoSmithKline
- Series A, Sep 7, 2005, $14M — Latterell Venture Partners, Morgenthaler Ventures, US Venture Partners, Vertical Group

## Investors

- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series A, Series C, Series B
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series C, Series B
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series A, Series C, Series B
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series C, Series B
- Bay Partners (https://capitalatlas.ai/funds/bay-partners) — Series C, Series B
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series C, Series B
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series C
- GlaxoSmithKline — Series C
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B
- Nomura Asset Management (https://capitalatlas.ai/funds/nomura-asset-management) — Series B
- GSK Ventures — Series B